中晚期肝癌肝动脉化疗栓塞介入治疗38例

Hepatic arterial chemoembolization interventional therapy 38 cases in advanced hepatocarcinoma

目的:探讨中晚期肝癌肝动脉化疗栓塞的疗效及影响疗效的因素。方法:对38例不能切除的原发性肝癌行选择性肝动脉插管灌注化疗。结果:选择性肝动脉插管灌注化疗栓塞0·5、1和2年生存率分别为60·5%(23/38)、26·3%(10/38)和0·3%(1/38),平均生存期为7·9个月。肿块类型与大小、栓塞剂及用量和甲胎蛋白的变化是影响疗效的主要因素。结论:选择性肝动脉插管灌注化疗栓塞可作为中晚期肝癌的常规治疗方法。

Objective To evaluate the therapeutic efficacy of hepatic arterial chemoembolization （HACE） and factors influencing efficacy.Methods 38 unresectable primary hepatocarcinoma were performed selective transcatheter arterial perfusion chemotherapy （TAPC）.Results The survival rates at 0.5,1 and 2 year of TAPe were 60.5% （23/38）,26.3% （10/38） and 0.3%（1/38）. The main factors influencing therapeutic effect were the typing and size of tumor, embolizing agents and their dosage and the change of alpha fetoprotein（AFP）.Conclusion HACE can be used routinely for treating advanced hepatocarcinoma.